Gelmann E P, Longo D, Lane H C, Fauci A S, Masur H, Wesley M, Preble O T, Jacob J, Steis R
Am J Med. 1987 Mar;82(3):456-62. doi: 10.1016/0002-9343(87)90445-1.
Two clinical trials were conducted to assess the efficacy and safety of a combination chemotherapy regimen for the treatment of Kaposi's sarcoma in patients with the acquired immune deficiency syndrome (AIDS). Eighteen consecutive patients with disseminated Kaposi's sarcoma were treated with a six-drug regimen of doxorubicin (Adriamycin), vinblastine, bleomycin/actinomycin D, vincristine, dacarbazine (ABV/ADV). A brief partial or complete response was achieved in 13 patients. Most patients died of opportunistic infections. Eighteen consecutive patients with disseminated Kaposi's sarcoma were then randomly assigned to therapy with either recombinant alpha interferon or ABV/ADV. The treatment responses in these two groups were comparable to results of earlier trials, and the incidence of opportunistic infections during therapy did not differ between the two treatment arms. It is concluded that chemotherapy is effective and safe for use in palliative management of Kaposi's sarcoma in patients with AIDS.
开展了两项临床试验，以评估一种联合化疗方案治疗获得性免疫缺陷综合征（AIDS）患者卡波西肉瘤的疗效和安全性。连续18例播散性卡波西肉瘤患者接受了包含阿霉素（阿霉素）、长春碱、博来霉素/放线菌素D、长春新碱、达卡巴嗪的六药方案（ABV/ADV）治疗。13例患者实现了短暂部分缓解或完全缓解。大多数患者死于机会性感染。随后，连续18例播散性卡波西肉瘤患者被随机分配接受重组α干扰素或ABV/ADV治疗。这两组的治疗反应与早期试验结果相当，且两个治疗组在治疗期间机会性感染的发生率无差异。得出的结论是，化疗用于AIDS患者卡波西肉瘤的姑息治疗是有效且安全的。
